Targeting Oncogenic Driver Mutations in Lung Cancer
Targeting Oncogenic Driver Mutations in Lung Cancer
Looking for an examination copy?
If you are interested in the title for your course we can consider offering an examination copy. To register your interest please contact collegesales@cambridge.org providing details of the course you are teaching.
The recent advances in the field of molecular diagnostic techniques have led to the identification of targetable alterations prompting a paradigm shift in the management of non-small cell lung cancer (NSCLC) and an era of precision oncology. This Element highlights the most clinically relevant oncogenic drivers other than EGFR, their management and current advancements in treatment. It also examines the different challenges in resistance to targeted therapies and diagnostic dilemmas for each oncogenic driver and the future direction of NSCLC management.
Product details
- Published: January 2023
- Format: Adobe eBook Reader
- ISBN: 9781009336109
- Length: 0 pages
- Availability: This ISBN is for an eBook version which is distributed on our behalf by a third party.
Table of Contents
- 1. Introduction
- 2. ALK gene rearrangements
- 3. ROSI gene rearrangements
- 4. RET gene rearrangements
- 5. MET alterations
- 6. KRAS point mutations
- 7. B-RAF point mutations
- 8. NTRK1/2/3 gene fusions
- 9. ERBB2 (HER2) mutations
- 10. Diagnostic strategies
- References.
- Show more
